Company profile: Axsome Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for neurological disorders, including Auvelity for major depressive disorder and Sunosi to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy; developing AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for acute migraine, and AXS-12 for narcolepsy.
Products and services
- AXS-05: An investigational NMDA receptor antagonist with multimodal activity, being developed for Alzheimer's disease agitation and smoking cessation
- Auvelity: An extended-release tablet combining dextromethorphan hydrobromide and bupropion hydrochloride for the treatment of major depressive disorder
- Sunosi: A tablet containing solriamfetol, used to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Axsome Therapeutics
VistaGen Therapeutics
HQ: United States
Website
- Description: Provider of investigational biopharmaceutical therapies for CNS diseases and disorders: Fasedienol (for multiple anxiety disorders), Itruvone (for major depressive disorder and other depression-related conditions), PH80 (menopausal hot flashes, premenstrual dysphoric disorder, migraines), PH15 (to improve cognition), PH284 (appetite-related disorders, including Cachexia), AV-101 (oral prodrug targeting the NMDA receptor glycine site).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VistaGen Therapeutics company profile →
NLS Pharmaceutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage drug development focused on neurobehavioral and neurocognitive disorders and their pharmacognosia, using a patient-centered, target-specific approach via collaborations with industry and academia. Products include Quilience, an extended-release mazindol for excessive daytime sleepiness and cataplexy in narcolepsy, and Nolazol, a controlled-release mazindol for ADHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NLS Pharmaceutics company profile →
Ad-Tech Medical
HQ: United States
Website
- Description: Provider of intra-cranial monitoring devices (electrodes) for the treatment of intractable epilepsy and neurosurgical instrumentation. Offerings include depth, subdural grid and strip, and foramen ovale electrodes for long-term EEG monitoring, mapping, SEEG, and intraoperative use; placement instruments and accessories for precise electrode placement; and connection systems to link electrodes to standard clinic EEG equipment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ad-Tech Medical company profile →
Longeviti Neuro Solutions
HQ: United States
Website
- Description: Provider of implantable neurosurgical devices, developing and commercializing these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Longeviti Neuro Solutions company profile →
Anelixis Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage drug development focused on immune modulatory therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD); facilitates pre-clinical drug development. Based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anelixis Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Axsome Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Axsome Therapeutics
2.2 - Growth funds investing in similar companies to Axsome Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Axsome Therapeutics
4.2 - Public trading comparable groups for Axsome Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →